Girentuximab (trade name Rencarex) is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX).

It is investigational agent in clinical trials for renal cell carcinoma.

[2] Its development was suspended as a "naked" or unconjugated antibody during phase III trials due to efficacy.

It was granted fast track status and orphan drug designation by the FDA for renal cancer.

[5] In January 2017, Telix Pharmaceuticals Limited, an Australian biotechnology company, announced that it had in-licensed Girentuximab for use as a radioimmunoconjugate.